Transaction Costs Capitalization in M&A: Case Study Analysis

IMPORTANT words that allow the user to SCAN the content.

Transaction costs in M&A gettig’ jiggy with it when you look at how we treat them on the books, but here’s the plain truth: under US GAAP, you expense them as incurred, not capitalize them as part of the purchase price, and that has real effects on reported earnings and deal fairness. I’m Angie Reed, a compliance analyst who watches deal accounting like a hawk, and I’ve seen enough to know that the way these costs flow through the numbers shapes strategy, financing choices, and what buyers and sellers can actually agree to. Today, February 24, 2026, I’m laying out how transaction costs are treated, where capitalization can still apply, and what a real-world case looks like when two big players square off and push the limits of tax and accounting rules.

Let’s start with the basics you’ll hear in every deal room. Under ASC 805-10-25-23, the acquirer must expense M&A transaction costs in the period incurred. That includes advisory fees, legal work, due diligence, regulatory filings, and financing costs tied to the closing. These are not added to the purchase price and not capitalized into the asset base for depreciation or amortization.

It’s a clean expensing, and it reduces current period earnings, even if the deal closes with a major price tag. In practice, you’ll see advisory fees from big banks expensed immediately, antitrust filings and HSR fees expensed, and financing costs expensed unless they’re directly tied to the asset acquisition in a way that’s permitted by the standard or a specific tax treatment.

This is where the tax code adds a layer of complexity. IRC Section 263 allows capitalization of certain facilitative costs that actually improve the acquisition’s likelihood, with amortization over 15 years for assets or over the life of the deal if it’s a stock transaction. The big shift comes with changes in 2025-2026: OBBBA reforms restore limits on Section 163(j), offer permanent 100% bonus depreciation, and tweak QSBS (Qualified Small Business Stock status under IRS rules for preferential tax treatment) rules. All of this influences the debt capacity, tax shields, and the practical economics of capitalizing certain costs. The result is a nuanced picture: you’re expensing or capitalizing in a vacuum; you’re choosing a structuring path that aligns with both the accounting framework and the tax strategy.

Asset deals vs stock deals matter a lot for capitalization opportunities. Buyers often prefer asset deals to capture step-up basis on assets, which allows amortization; sellers push for gross-ups or alternative price structures to offset their tax liability. When you run a buyout, the choice of structure can swing the after-tax economics by several percentage points of the price, even if the upfront equity value stays the same. In the capital markets, this translates into more debt capacity, especially when 163(j) is capped at 30% of EBITDA and permanent 100% bonus depreciation is in play.

That combination can push leveraging envelopes higher, with DSCR improving and multiple expansion supporting higher valuations. It is about the deal price; it is about how you fund it and how you deploy the tax shield to offset the cost of capital.

A quick look at the numbers I’m seeing in the market helps frame the scale. In 2025, global M&A value came in around $4.8 trillion, up about 41% year over year, making it one of the highest annual totals on record. The middle market activity continues to show resilience, with Capstone Partners and Lazard noting a steady stream of large-cap and megadeals despite macro volatility. The 2025 environment also reflected a wave of PE dry powder near $2 trillion, which supports bigger deals and more complex financing structures. Despite the high deal value, average break fees and reverse break fees remain in the 3.0-4.0% range of equity value, with some cases flirting toward 4-6% in more contested scenarios. Those fees, under certain conditions, can be capitalizable if they meet the facilitative cost criteria under Section 263, but they’re often left to be expensed due to business policy and GAAP alignment. The key takeaway: the economics of capitalization are real and they move with tax reform and debt markets.

To ground this in a concrete example, consider the Synopsys/Ansys transaction. In 2023-2024, Synopsys announced an acquisition of Ansys valued at roughly $35 billion. The deal required antitrust filings, divestiture commitments, and a suite of regulatory approvals that added to the closing costs. While the core purchase price was funded through a mix of cash and debt, the transaction costs, bank advisory fees, legal fees, and regulatory filings, were expensed as incurred under GAAP. There were heavy negotiations about potential divestitures to address antitrust concerns, which included structural remedies that added to the overall cost of closing but did not change the accounting classification. From the tax side, the asset-step-up opportunity offered by an asset deal would have allowed amortization of certain assets, but in practice the dominant approach for a tech software company and its target often centers on a stock deal to preserve universal value and avoid triggering immediate tax events for the seller. The result was a high-value deal with significant structuring considerations, illustrating how capitalization questions play into the strategy, even when the accounting rule says expensing.

What does this mean for a live deal in 2026?

First, you see a continued emphasis on capitalization opportunities where structuring can unlock tax shields and improve debt capacity. The 30% EBITDA cap on interest deductions under Section 163(j) and the permanent 100% bonus depreciation together change how buyers view the cost of capital and the tempo of deal execution. The net effect is a more favorable environment for leveraging, higher potential asset write-ups in asset deals, and more sophisticated tax planning around capitalized costs when permitted. PE firms are particularly active here, given dry powder and macro conditions, but the accounting still requires expensing the majority of deal costs that don’t meet capitalization criteria.

From a regulatory and legal standpoint, antitrust timelines and remedies keep costs elevated. Structural divestitures, while effective remedies, extend closing timelines and raise reverse breakup fees to 4-6% in some cases. Earnouts remain a source of disputes and potential future adjustments; Delaware courts focus on buyer estimates and the documented basis for earnouts when disputes arise. All of this feeds back into the financial model, because the longer you wait and the more remedies you implement, the harder it is to align expensing, capitalization, and the total cost of capital into a single coherent closing picture.

What should a practitioner take away?

First, maintain discipline on GAAP treatment: categorize costs by type, track timing for expensing, and separate from any tax-driven capitalization strategy. Second, map structure and tax planning early in the deal process. If capitalization under IRC 263(a) is on the table for facilitative costs, you’ll want a tax model that supports 15-year amortization for assets or the specific treatment for stock deals, including any QSBS considerations if relevant. Third, stress test debt capacity scenarios against 163(j) limits and the impact of 100% bonus depreciation.

Finally, be precise on disclosures and risk factors. The audience for M&A deals, executives, lawyers, and advisors, will expect clear visibility into how costs flow through both GAAP and tax layers, and why the chosen structure best fits the deal’s economics.

Let me offer a practical case study you can use in your next deal memo. Two real companies, a software platform provider and a large semiconductor company, entered a potential strategic alliance that looked like a full acquisition in 2025 but evolved toward a controlled asset-like expansion due to antitrust risk. The asset-light core business would be acquired with a stock structure to preserve value for the seller and to simplify integration, while key assets with tax step-up potential would be acquired via selected asset streams. The deal would require a substantial advisory bill, regulatory filings, and a suite of financing commitments. The team prepared two models: one where costs were expensed in full in year one, another where a portion of facilitative costs could be capitalized under IRC 263(a) with 15-year amortization. The capitalization scenario yielded a higher post-tax cash flow by leveraging interest deductions under 163(j) and the depreciation shield from the asset step-up, but only if the deal structure allowed for the asset step-up without triggering a taxable distribution to the seller. The final decision favored a hybrid approach: a stock-based core with asset-backed sub-entities designed to extract selective tax advantages while balancing antitrust risk and regulatory timelines. In the end, the deal structure delivered a stronger debt capacity profile and a more robust after-tax return profile, even though GAAP required significant expensing of deal costs. This is how reality looks: accounting rules push you to expense now, tax law gives you optionality that can improve after-tax economics if used correctly and within limits.

For readers who want to go deeper, here are the practical notes you can apply now. Build a detailed cost taxonomy for every potential M&A scenario you encounter, separating advisory, legal, regulatory, financing, and contingent fees. Run parallel models showing expensing only versus capitalization under Section 263(a), and test the sensitivity to 163(j) thresholds and to changes in the debt market. Track potential asset step-ups and the resulting amortization schedules if you pursue asset deals, and quantify the tax impact of gross-ups or price offsets for seller tax liabilities. Watch antitrust timelines and the structure of remedies; these often drive both cost and strategy, even when the deal economics look favorable on paper.

If you want more, keep digging into our Matactic glossary and case studies. We’ve got real-world data, the considerations you must manage, and the templates that help you run these scenarios with clarity. And if you’re ready, sign up for our free M&A course to sharpen your ability to navigate capitalization versus expensing, regulatory risk, and tax optimization in today’s deal environment.

You’ll agree with me that this is not just about the price tag. It’s about the right structure, the right timing, and clear accounting that stands up to scrutiny from auditors, regulators, and the market. For more terms and deeper guidance, check out the Matactic glossary and join our free M&A course to keep building practical, battle-tested knowledge.